SAGE - HAGENS BERMAN NATIONAL TRIAL ATTORNEYS Encourages Sage Therapeutics (SAGE) Investors with Substantial Losses to Contact Firm's Attorneys Firm Investigating Possible Securities Law Violations | Benzinga

SAN FRANCISCO, Aug. 28, 2023 (GLOBE NEWSWIRE) -- Hagens Berman urges Sage Therapeutics, Inc. (NASDAQ:SAGE) investors who suffered substantial losses to submit your losses now.

Visit: www.hbsslaw.com/investor-fraud/sage
Contact An Attorney Now: SAGE@hbsslaw.com
                                                844-916-0895

Sage Therapeutics, Inc. (NASDAQ:SAGE) Investigation:

The investigation focuses on Sage's disclosures concerning its New Drug Application for the use of zuranolone for treating adults with postpartum depression ("PPD") and adults with major depressive disorder ("MDD").

The accuracy of Sage's disclosures came into question on Aug. 4, 2023, when the company announced that, while the FDA approved zuranolone for treating adults with PPD, the FDA issued a complete response letter rejecting ...

SAGE) Investors with Substantial Losses to Contact Firm's Attorneys, Firm Investigating Possible Securities Law Violations>Full story available on Benzinga.com